Dr. E. David Crawford spoke at the 23rd annual Perspectives in Urology Point • Counterpoint meeting on Sunday, November 16, 2014 on “Risk of Renal and Cardiovascular Side Effects with ADT.”

 

Keywords: renal cell carcinoma (RCC), cardiovascular side effects, ADT

How to cite: Crawford, E. David. “Risk of Renal and Cardiovascular Side Effects with ADT” Grand Rounds in Urology. July 15015. Accessed Mar 2024. https://grandroundsinurology.com/prostate-cancer-e-david-crawford-side-effects-withadt/.

References

Chawla LS, Amdur RL, Amodeo S, et al. The severity of acute kidney injury predicts progression to chronic kidney disease. Kidney Int. 2011 Jun;79(12):1361-9.
http://www.ncbi.nlm.nih.gov/pubmed/21430640

Chen HF, Jeung EB, Stephenson M, et al. Human peripheral blood mononuclear cells express gonadotropin-releasing hormone (GnRH), GnRH receptor, and interleukin-2 receptor gamma-chain messenger ribonucleic acids that are regulated by GnRH in vitro. J Clin Endocrinol Metab. 1999 Feb;84(2):743-50.
http://www.ncbi.nlm.nih.gov/pubmed/10022447

Chertow GM, Burdick E, Honour M, et al. Acute kidney injury, mortality, length of stay, and costs in hospitalized patients. J Am Soc Nephrol. 2005 Nov;16(11):3365-70.
http://www.ncbi.nlm.nih.gov/pubmed/16177006

Chung SD, Liu SP, Lin HC, et al. Increased risk of pneumonia in patients receiving gonadotropin-releasing hormone agonists for prostate cancer. PLoS One. 2014 Jun 27;9(6).
http://www.ncbi.nlm.nih.gov/pubmed/24971988

Dansky HM, Charlton SA, Harper MM, et al. T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4642-6.
http://www.ncbi.nlm.nih.gov/pubmed/9114044

Dixit VD, Yang H, Udhayakumar V, et al. Gonadotropin-releasing hormone alters the T helper cytokine balance in the pregnant rat. Biol Reprod. 2003 Jun;68(6):2215-21.
http://www.ncbi.nlm.nih.gov/pubmed/12606332

Kambham N, Markowitz GS, Valeri AM, et al. Obesity-related glomerulopathy: an emerging epidemic. Kidney Int. 2001 Apr;59(4):1498-509.
http://www.ncbi.nlm.nih.gov/pubmed/11260414

Klotz L, Miller K, Crawford ED, et al. Disease control outcomes from analysis of pooled individual patient data from five comparative randomised clinical trials of degarelix versus luteinising hormone-releasing hormone agonists. Eur Urol. 2014 Dec;66(6):1101-8.
http://www.ncbi.nlm.nih.gov/pubmed/24440304

Jespersen CG, Nørgaard M, Borre M. Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study. Eur Urol. 2014 Apr;65(4):704-9.
http://www.ncbi.nlm.nih.gov/pubmed/23433805

Keating NL, O’Malley AJ, Freedland SJ, et al. Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer. J Natl Cancer Inst. 2010 Jan 6;102(1):39-46.
http://www.ncbi.nlm.nih.gov/pubmed/19996060

Lapi F, Azoulay L, Niazi MT, et al. Androgen deprivation therapy and risk of acute kidney injury in patients with prostate cancer. JAMA. 2013 Jul 17;310(3):289-96.
http://www.ncbi.nlm.nih.gov/pubmed/23860987

Molinari C, Battaglia A, Grossini E, et al. The effect of testosterone on regional blood flow in prepubertal anaesthetized pigs. J Physiol. 2002 Aug 15;543(Pt 1):365-72.
http://www.ncbi.nlm.nih.gov/pubmed/12181306

Nguyen PL, Alibhai SM, Basaria S, et al. Adverse effects of androgen deprivation therapy and strategies to mitigate them. Eur Urol. 2015 May;67(5):825-36.
http://www.ncbi.nlm.nih.gov/pubmed/25097095

Schiffl H, Lang SM. Current practice of conventional intermittent hemodialysis for acute kidney injury. Indian J Nephrol. 2013 Nov;23(6):395-402.
http://www.ncbi.nlm.nih.gov/pubmed/24339514

Schiffl H, Lang SM, Fischer R. Long-term outcomes of survivors of ICU acute kidney injury requiring renal replacement therapy: a 10-year prospective cohort study. Clin Kidney J. 2012 Aug;5(4):297-302.
http://www.ncbi.nlm.nih.gov/pubmed/25874084

Tanriverdi F, Gonzalez-Martinez D, Hu Y, et al. GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males. Clin Exp Immunol. 2005 Oct;142(1):103-10.
http://www.ncbi.nlm.nih.gov/pubmed/16178862

Van Hemelrijck M, Garmo H, Holmberg L, et al. Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden. J Clin Oncol. 2010 Jul 20;28(21):3448-56.
http://www.ncbi.nlm.nih.gov/pubmed/20567006